{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021838","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.432032+00:00","generated_at":"2026-06-22T08:33:19.834340+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Syndax Q3 net loss $35.4M; revumenib Phase 1 shows 30% CR/CRh rate, 9.1 mo median durability","bullets":["Net loss $35.4M ($0.58 per share) vs $20.6M ($0.40) prior year; cash $337.8M at Sep 30.","Revumenib Phase 1 CR/CRh rate 30% (18/60); median response 9.1 months; 75% of transplanted patients in remission.","Enrollment complete in pivotal AGAVE-201 trial of axatilimab in cGVHD; topline data expected mid-2023.","Lowered FY 2022 R&D expense guidance to $115-125M and total op ex to $145-155M, citing axatilimab cost sharing.","On track for revumenib NDA and axatilimab BLA filings by end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021838","json":"https://secwatch.observer/filing/0000950170-22-021838.json","markdown":"https://secwatch.observer/filing/0000950170-22-021838.md","text":"https://secwatch.observer/filing/0000950170-22-021838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017022021838/0000950170-22-021838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017022021838/sndx-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:33:19.834340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17a55e37807696c01e2f12edaec57ad3b5c3470f","claim":"Syndax Pharmaceuticals Inc reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 3, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017022021838/0000950170-22-021838-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}